Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
We are a global commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of patients with cancer and immunological diseases. Our company started in China in 2000 and has since developed fully integrated capabilities and expanded oncology and immunology drug development operations globally. Our operational achievements and capabilities to date include:
In the company’s own words · 20-F filed Mar 5, 2026 · SEC EDGAR
HUTCHMED (China) Limited (HCM) reported revenue of $271M in H2 2025 (quarter ended December 31, 2025), down 11% from the same quarter a year earlier. That came with a gross margin of 38% and net income of $2.0M (0.7% of revenue). For the full year FY2025, revenue was $549M (−13% year on year) and net income $457M.
Raw charts
9 series · TTMAs reported to the SEC, without any scoring.
Drug Manufacturers - Specialty & Generic
The closest names by size in the same industry